BlackRock Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

BlackRock Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$519K	Buy	39,187 +1,205	+3%	+$20.6K	﹤0.01%	2188
2016 Q3	$900K	Sell	37,982 -59,808	-61%	-$1.61M	﹤0.01%	1876
2016 Q2	$2.82M	Buy	97,790 +1,960	+2%	+$63.9K	﹤0.01%	1313
2016 Q1	$3.07M	Buy	95,830 +65,853	+220%	+$2.32M	﹤0.01%	1275
2015 Q4	$1.28M	Sell	29,977 -14,561	-33%	-$582K	﹤0.01%	1601
2015 Q3	$1.57M	Sell	44,538 -1,509	-3%	-$68K	﹤0.01%	1442
2015 Q2	$2.11M	Buy	46,047 +2,720	+6%	+$129K	﹤0.01%	1247
2015 Q1	$2.03M	Buy	43,327 +6,015	+16%	+$239K	﹤0.01%	1220
2014 Q4	$1.18M	Sell	37,312 -1,912	-5%	-$56K	﹤0.01%	1401
2014 Q3	$930K	Sell	39,224 -911	-2%	-$23.3K	﹤0.01%	1478
2014 Q2	$1.2M	Sell	40,135 -5,922	-13%	-$160K	﹤0.01%	1383
2014 Q1	$1.22M	Buy	46,057 +2,047	+5%	+$51.2K	﹤0.01%	1409
2013 Q4	$1.11M	Buy	44,010 +3,444	+8%	+$76.8K	﹤0.01%	1453
2013 Q3	$830K	Buy	40,566 +192	+0.5%	+$3.96K	﹤0.01%	1538
2013 Q2	$805K	Buy	+40,374	New	+$717K	﹤0.01%	1495

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Advisors's IPXL Position: Q4 2016 in Review

BlackRock Advisors increased its Impax Laboratories, Inc. (IPXL) stake by 3.2% in Q4 2016, buying an estimated $20.6K and bringing the position to 39,187 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

BlackRock Advisors first reported a position in IPXL in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.07M in Q1 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

BlackRock Advisors held 39,187 shares of Impax Laboratories, Inc. worth $519K as of Q4 2016.
BlackRock Advisors bought 1,205 Impax Laboratories, Inc. shares in Q4 2016, an estimated $20.6K.
Impax Laboratories, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2188 holding.
BlackRock Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Impax Laboratories, Inc. position peaked at $3.07M in Q1 2016.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.